Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological markers for breast carcinoma.

T P Waalkes, J P Enterline, J H Shaper

    Cancer
    |February 1, 1984
    PubMed
    Summary

    Researchers are seeking reliable breast cancer biomarkers. While plasma carcinoembryonic antigen (CEA) shows promise for monitoring metastasis and recurrence, a specific, sensitive marker for early detection remains elusive.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    Erasable Western blots.

    Methods in molecular biology (Clifton, N.J.)·2012
    Same author

    Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330.

    Sarcoma·2012
    Same author

    Erasable Western blots.

    Methods in molecular biology (Clifton, N.J.)·2012
    Same author

    Regionalization of cancer control efforts in the u.s.a.

    International quarterly of community health education·2010
    Same author

    Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial.

    Clinical lung cancer·2004

    Area of Science:

    • Oncology
    • Biochemistry

    Background:

    • Intense research for breast carcinoma biological markers over the last decade.
    • Existing markers in body fluids lack specificity and sensitivity for early detection or low tumor burden assessment.
    • Biological variations can complicate marker data interpretation.

    Purpose of the Study:

    • To review the current status of biological markers for breast cancer.
    • To evaluate the utility of plasma carcinoembryonic antigen (CEA) in breast cancer management.
    • To highlight promising future research directions for breast cancer marker discovery.

    Main Methods:

    • Review of existing literature on breast cancer biomarkers.
    • Analysis of the evaluation and clinical application of plasma carcinoembryonic antigen (CEA).
    • Discussion of emerging techniques, including monoclonal antibody-based marker identification.

    Main Results:

    • Plasma CEA is elevated in 60%-70% of metastatic breast cancer patients, with levels often proportional to tumor burden.
    • Changes in CEA levels correlate with treatment response and disease progression.
    • Serial CEA measurements post-mastectomy may aid in predicting recurrence risk.

    Conclusions:

    • Plasma CEA is a valuable tool for monitoring metastatic breast cancer and predicting recurrence.
    • A highly specific and sensitive biomarker for early breast cancer detection is still needed.
    • Monoclonal antibody techniques offer a promising avenue for discovering novel, specific breast cancer markers.

    Related Experiment Videos